Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02035358 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy Study for Metastatic Renal Cell Cancer
A Phase 1 study, sponsored by NewLink Genetics Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02035358 is a Phase 1 study that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 18 participants.
The verdict
NCT02035358, a Phase 1 study, has completed, sponsored by NewLink Genetics Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
In this Phase 1 Trial investigators plan to establish the MTD of HyperAcute®-Renal (HAR) immunotherapy in subjects with clinically metastatic renal cell carcinoma.
Interventions
- BIOLOGICAL HyperAcute®-Renal (HAR) Immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-05 |
| Est. Completion | 2021-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02035358
The ClinicalTrials.gov registry entry for NCT02035358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HyperAcute®-Renal (HAR) Immunotherapy is the first listed.
NCT02035358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02035358 about?
NCT02035358 is a clinical study titled "Immunotherapy Study for Metastatic Renal Cell Cancer". In this Phase 1 Trial investigators plan to establish the MTD of HyperAcute®-Renal (HAR) immunotherapy in subjects with clinically metastatic renal cell carcinoma.
What is the current status of trial NCT02035358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-05. Estimated completion is 2021-01-12.
What interventions are being tested in trial NCT02035358?
The interventions under investigation include: HyperAcute®-Renal (HAR) Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT02035358?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.